AMAG Pharmaceuticals — Q3 2018 Earnings Presentation
29 slides from AMAG Pharmaceuticals's earnings presentation, Nov 1, 2018
Slide 1: Q3-2018 Financial Results
Q3-2018 Financial Results November 1, 2018 © 2018 AMAG Pharmaceuticals, Inc. All rights reserved 1
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward‐looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA) and other federal securities laws. Any statements contained herein which do not describe historical facts, including, among others, expe
Slide 3: Agenda
Agenda 1 Q3-2018 Highlights 2 Commercial Product Portfolio Update 3 Q3-2018 Financial Overview 4 Value Drivers 5 Q&A © 2018 AMAG Pharmaceuticals, Inc. All rights reserved 3
Slide 4: Third Quarter 2018 Highlights and Recent Developments
Third Quarter 2018 Highlights and Recent Developments 42% Feraheme revenue growth year over year Completed the sale of CBR • Underscores focus on development and commercialization of pharmaceutical products Makena brand revenue from subcutaneous (SC) $475M high yield notes paid-off 57% auto-injector
Slide 5: Feraheme Makena Intrarosa
Feraheme Makena Intrarosa 5
Slide 6: Feraheme Continues to Grow with Expanded Label
Feraheme Continues to Grow with Expanded Label Feraheme Revenue1 ($M) Feraheme Growth $37.0 • Q3-2018 vs. Q3-2017 – Volume increased by 31% – Market share rose from 12.3% to 15.8%2 42% $26.1 – Performance based contracting supports increased net price by 11% • Launched OB/GYN IV iron pilot program u
Slide 7: Feraheme Continues to Grow with Expanded Label: Market Share
Feraheme Continues to Grow with Expanded Label Feraheme volume demand grew versus Q2-2018, despite INFeD return IV Iron Deficiency Anemia (IDA) Quarterly Market Share by Product3 Q3 INFeD Return to Market Impact4 Ferrlecit / Q3-2018 Q3 vs. Q2 INFeD Feraheme Injectafer Venofer Total Nulecit 5.9% Mark
Slide 8: Feraheme Makena Intrarosa
Feraheme Makena Intrarosa 8
Slide 9: Continued Strong Conversion from Makena IM to SC Auto-injector
Continued Strong Conversion from Makena IM to SC Auto-injector 57% of Q3-2018 Makena brand revenue from subcutaneous auto-injector Makena Revenue ($M) Q3-2018 Results $105.2 • Continued strong conversion from IM to SC auto-injector $97.6 – 57% of brand revenue from SC auto-injector $80.2 • First gen
Slide 10: Optimize Makena Franchise Performance & Sustainability
Optimize Makena Franchise Performance & Sustainability Protect the Brand Participate in Generic Market • Continue to convert usage to Makena SC auto-injector • Partnered with Prasco, an experienced – Promote the benefits of the SC auto-injector authorized generic company – Brand loyalty: 56% of Q3 s
Slide 11: Feraheme Makena Intrarosa
Feraheme Makena Intrarosa 11
Slide 12: Intrarosa HCP Prescribing and Market Share Continue to Increase
Intrarosa HCP Prescribing and Market Share Continue to Increase 6 Intrarosa Rx Volume As of September 30, 2018 (data reported as of last week of each month) 5,000 • >146,000 TRx’s written since launch7 4,500 – Increase of 53,000 since June 30 4,000 • 11,300 HCP prescribers since launch7 3,500 – Incr
Slide 13: September Campaigns Kick Started Integrated Direct-to-Consumer Program
September Campaigns Kick Started Integrated Direct-to-Consumer Program Condition Awareness Campaign Branded Campaign Patient Consults MD Cheryl Hines, Emmy®-nominated actress Office visit or on-line 360M+ impressions 650K unique visitors to site 10M+ women reached in Sept 40% ahead of benchmark 2x b
Slide 14: Financial Overview
Financial Overview 14
Slide 15: Revenue, Operating Loss and Adjusted EBITDA
Revenue, Operating Loss and Adjusted EBITDA ($M)* Q3-2017 Q3-2018 $124.3 $0.4 $122.2 $4.9 • Makena SC auto-injector revenue of $40M $97.6 $80.2 • Feraheme revenue growth of 42% $45.1 • Q3-2017 operating loss includes $319M 45.1 $30.0 impairment charge and $50M expense reversal 30 $26.3 $37.1 • Q3-20
Slide 16: 2018 Financial Guidance
2018 Financial Guidance* Strong execution throughout year resulted in three upward guidance moves in 2018 Pharma Revenue Guidance $70M; Adjusted EBITDA $50M from January 2018 Guidance ($M) January 2018 May 2018 August 2018 November 2018 Total revenue $380 - $440 $420 - $460 $450 - $490 $470 - $490 O
Slide 17: 2018 Financial Results and Guidance
2018 Financial Results and Guidance Q4-2018 will be a period of continued investment to drive future value Updated November 2018 Guidance ($M) 9-Mos. 2018 Actual* Low Mid High Total revenue $385.9 $470 $480 $490 GAAP operating loss ($28.2) ($72) ($67) ($62) Non-GAAP Adjusted EBITDA $119.3 $115 $120
Slide 18: Strengthening Balance Sheet
Strengthening Balance Sheet ($M) 9/30/18 12/31/17 Cash, cash equivalents and investments $428 $3299 Short-term debt: Convertible senior notes (2.5%) due 2019 $ 21 $ 21 Long-term debt: Convertible senior notes (3.25%) due 2022 $320 $320 Senior notes (7.875%) due 2023 $ 0 $475 FINANCIAL OVERVIEW © 201
Slide 19: Significant Shareholder Value at AMAG
Significant Shareholder Value at AMAG Historical Value Drivers Fund Future Value Drivers AMAG-423 AMAG-423 ™ Vyleesi™ Vyleesi HISTORICAL Value at AMAG FUTURE (≥2020) Value at AMAG © 2018 AMAG Pharmaceuticals, Inc. All rights reserved 19
Slide 20: Significant Unmet Medical Need with Global Commercial Opportunity
Significant Unmet Medical Need with Global Commercial Opportunity AMAG-423 in development for the treatment of severe preeclampsia • Preeclampsia is the leading cause of:10 – Maternal morbidity and mortality – Adverse neonatal outcomes • No effective treatments for preeclampsia Annual U.S. incidence
Slide 21: Significant Unmet Medical Need for Millions of Women
Significant Unmet Medical Need for Millions of Women Vyleesi: investigational product for premenopausal women with HSDD* • Medical condition of low sexual desire/libido associated with distress • Novel mechanism of action – Melanocortin receptor agonist (MCR4) 12 million U.S. women with HSDD18 • Use
Slide 22: Significant Unmet Medical Need in Large Underserved Market
Significant Unmet Medical Need in Large Underserved Market Intrarosa: First-in-class therapy to treat moderate to severe dyspareunia • Dyspareunia – Common symptom of VVA* in post- menopausal women • Only FDA approved locally administered non-estrogen therapy22 Annual U.S. incidence of dyspareunia,
Slide 23: Innovative Pipeline Delivering Multiple Value Drivers
Innovative Pipeline Delivering Multiple Value Drivers Approved/ PHASE 1 PHASE 2 PHASE 3 Regulatory Review Marketed AMAG-423 Digoxin Immune Treatment of severe preeclampsia 2020 2021 Fab (ovine) Treatment of low desire or libido with PDUFA TM AdCom: January 2019 Vyleesi associated distress in premeno
Slide 24: Q&A
Q&A © 2018 AMAG Pharmaceuticals, Inc. All rights reserved 24
Slide 25: Appendix
Appendix 25
Slide 26: Reconciliation of GAAP to Non-GAAP Financial Results
Reconciliation of GAAP to Non-GAAP Financial Results ($M) Q3-2017 Q3-2018 YTD-2018 GAAP operating loss ($254.2) ($19.3) ($28.2) Depreciation and intangible asset amortization 24.0 31.4 146.0 Non-cash inventory step-up adjustments 0.4 0.4 3.6 Stock-based compensation 5.6 5.0 14.6 Adjustments to conti
Slide 27: Reconciliation of GAAP to Non-GAAP 2018 Financial Guidance
Reconciliation of GAAP to Non-GAAP 2018 Financial Guidance Financial guidance issued throughout 201825 Updated ($M) January 2018 May 2018 August 2018 November 2018 GAAP operating loss ($169) – ($139) ($149) – ($129) ($75) - ($55) ($72) - ($62) Depreciation & intangible asset amortization 179 179 174
Slide 28: Endnotes
Endnotes 1. Represents Feraheme revenue only. Excludes MuGard revenue as reported on financial statements. 2. Feraheme market share based on IQVIA data and internal analytics. 3. Average quarterly market share of IV iron products based on IQVIA data. 4. Market share and volume data of IV iron produc
Slide 29: Q3-2018 Financial Results
Q3-2018 Financial Results November 1, 2018 © 2018 AMAG Pharmaceuticals, Inc. All rights reserved 29